PD-1 Antikörper

Produktnummer ABIN2665970

Der Maus Monoklonal Anti-PD-1 Antikörper wurde für FACS, WB und IHC validiert. Er ist geeignet, PD-1 in Proben von Human zu detektieren.

Kurzübersicht für PD-1 Antikörper (ABIN2665970)

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PD-1 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Western Blotting (WB), Immunohistochemistry (IHC)

Klon: EH12-2H7

Produktdetails anti-PD-1 Antikörper

Marke: Ultra-LEAF™

Kreuzreaktivität: Schimpanse, Marmoset, Rhesusaffen, Squirrel Monkey (Saimiri spec.), Cynomolgus

Aufreinigung: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau:

Endotoxin level is <0.01 EU/μg of the protein (<0.001 ng/μg of the protein) as determined by the LAL test.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Konservierungsmittel: Azide free

Handhabung: This Ultra-LEAF™ solution contains no preservative, handle under aseptic conditions

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu PD-1

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Andere Bezeichnung: CD279

Hintergrund: Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Pathways: Cancer Immune Checkpoints